

RESPONSE

I. Status of the Claims

No claims have been cancelled. Claim 2 has been amended. No new claims have been added. Claims 1-4 and 6-13 are therefore presently pending in the case.

II. Support for the Amended Claim

Claim 2 has been amended to recite specific highly stringent hybridization conditions. Support for these claims can be found throughout the specification as originally filed, with particular support being found at least at page 4, lines 15-22.

It will be understood that no new matter is included within the amended claim.

III. Rejection of Claims 1-4 and 6-13 Under 35 U.S.C. § 101

The Action first rejects claims 1-4 and 6-13 under 35 U.S.C. § 101, as allegedly lacking a patentable utility. Applicants respectfully traverse.

As set forth in Applicants' response filed on February 21, 2003 ("the previous response") to the First Office Action in this case, which was issued on September 25, 2002 ("the First Action"), the present invention has a number of substantial and credible utilities, not the least of which is in **forensic** analysis. As described in the specification from page 16, line 25 through page 17, line 2, the present sequences define two coding single nucleotide polymorphisms - specifically, a G/C polymorphism at position 212 of SEQ ID NO:1, which can lead to a glycine or alanine residue at amino acid position 71 of SEQ ID NO:2, and an A/C polymorphism at position 219 of SEQ ID NO:1, which can lead to a lysine or asparagine residue at amino acid position 73 of SEQ ID NO:2. The Action states that because the "associations between a disease and specific differences (SNPs) in a population" are not disclosed in the specification, the claimed sequence is not useful in "forensic analysis" (Action at page 4). This argument **completely** mischaracterizes Applicants' position. Applicants **once again** respectfully point out that the use of the presently described polymorphisms in **forensic** analysis does **not require the identification of a specific medical condition**. Applicants respectfully point out that the presently described polymorphisms are useful in forensic analysis exactly as they were described in the specification as originally filed - specifically, to distinguish individual members of the human

population based on the presence or absence of one or both of the described polymorphisms. Therefore, as such polymorphisms are the basis for **forensic** analysis, which is undoubtedly a “real world” utility, the present sequences must in themselves be useful. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

This is also not a case of a “potential” utility. Using the polymorphic markers exactly as described in the specification as originally filed can definitely distinguish members of a population from one another. In the worst case scenario, each marker is useful to distinguish 50% of the population (in other words, a marker being present in half of the population). The ability to eliminate 50% of the population from a forensic analysis clearly is a real world, practical utility. Therefore, any allegation that the use of the presently described polymorphic marker are only potentially useful would be without merit, and would not support the alleged lack of utility.

As set forth in the previous response, it is important to note that the presence of more useful polymorphic markers for forensic analysis would not mean that the present sequences lack a specific utility. As clearly set forth by the Federal Circuit in *Carl Zeiss Stiftung v. Renishaw PLC*, 20 USPQ2d 1101 (Fed. Cir. 1991):

An invention need not be the best or only way to accomplish a certain result, and it need only be useful to some extent and in certain applications: “[T]he fact that an invention has only limited utility and is only operable in certain applications is not grounds for finding a lack of utility.” *Envirotech Corp. v. Al George, Inc.*, 221 USPQ 473, 480 (Fed. Cir. 1984)

Just because other, or even more useful, polymorphic sequences from the human genome have been described does not mean that the use of the presently described polymorphic markers for forensic analysis is not a specific utility. If every invention were required to have a unique utility, the Patent and Trademark Office would no longer be issuing patents on batteries, automobile tires, golf balls, golf clubs, and treatments for a variety of human diseases, such as cancer, just to name a few particular examples, because the utility of each of these compositions is applicable to the broad class in which each of these compositions falls: all batteries have the same utility, specifically to provide electrical power; all automobile tires have the same utility, specifically for use on automobiles; all golf balls and golf clubs have the same utility, specifically for use in the game of golf; and all cancer treatments have the same utility, specifically, to treat cancer. However, only the briefest perusal of virtually any issue of the Official Gazette provides numerous examples of patents being granted on each of the above

compositions nearly every week. Furthermore, if a composition needed to be unique to be patented, the entire class and subclass system would be an effort in futility, as the class and subclass system serves solely to group such common inventions, which would not be required if each invention needed to have a unique utility. Thus, the present sequence clearly meets the requirements of 35 U.S.C. § 101.

Furthermore, as the presently described polymorphisms are part of the family of polymorphisms that have a well established utility, Applicants' reliance on *In re Brana*, (34 USPQ2d 1436 (Fed. Cir. 1995), "*Brana*") in the previous response is directly on point. In *Brana*, the Federal Circuit admonished the Patent and Trademark Office for confusing "the requirements under the law for obtaining a patent with the requirements for obtaining government approval to market a particular drug for human consumption". *Brana* at 1442. The Federal Circuit went on to state:

At issue in this case is an important question of the legal constraints on patent office examination practice and policy. The question is, with regard to pharmaceutical inventions, what must the applicant provide regarding the practical utility or usefulness of the invention for which patent protection is sought. This is not a new issue; it is one which we would have thought had been settled by case law years ago.

Brana at 1439, emphasis added. The choice of the phrase "utility or usefulness" in the foregoing quotation is highly pertinent. The Federal Circuit is evidently using "utility" to refer to rejections under 35 U.S.C. § 101, and is using "usefulness" to refer to rejections under 35 U.S.C. § 112, first paragraph. This is made evident in the continuing text in *Brana*, which explains the correlation between 35 U.S.C. §§ 101 and 112, first paragraph. The Federal Circuit concluded:

FDA approval, however, is not a prerequisite for finding a compound useful within the meaning of the patent laws. Usefulness in patent law, and in particular in the context of pharmaceutical inventions, necessarily includes the expectation of further research and development. The stage at which an invention in this field becomes useful is well before it is ready to be administered to humans. Were we to require Phase II testing in order to prove utility, the associated costs would prevent many companies from obtaining patent protection on promising new inventions, thereby eliminating an incentive to pursue, through research and development, potential cures in many crucial areas such as the treatment of cancer.

Brana at 1442-1443, citations omitted, emphasis added. As set forth above, the present polymorphisms are useful in forensic analysis exactly as they were described in the specification as originally filed, without the need for any further research. Even if the use of these polymorphic markers provided additional information on the percentage of particular subpopulations that contain these

polymorphic markers, this would not mean that “additional research” is needed in order for these markers as they are presently described in the instant specification to be of use to forensic science. As stated above, using these polymorphic markers as described in the specification as originally filed can definitely distinguish members of a population from one another. However, even if, *arguendo*, further research might be required in certain aspects of the present invention, this does not preclude a finding that the invention has utility, as set forth by the Federal Circuit’s holding in *Brana*, which clearly states, as highlighted in the quote above, that “pharmaceutical inventions, necessarily includes the expectation of further research and development” (*Brana* at 1442-1443, emphasis added). In assessing the question of whether undue experimentation would be required in order to practice the claimed invention, the key term is “undue”, not “experimentation”. *In re Angstadt and Griffin*, 190 USPQ 214 (CCPA 1976). The need for some experimentation does not render the claimed invention unpatentable. Indeed, a considerable amount of experimentation may be permissible if such experimentation is routinely practiced in the art. *In re Angstadt and Griffin, supra; Amgen, Inc. v. Chugai Pharmaceutical Co., Ltd.*, 18 USPQ2d 1016 (Fed. Cir. 1991). As a matter of law, it is well settled that a patent need not disclose what is well known in the art. *In re Wands*, 8 USPQ 2d 1400 (Fed. Cir. 1988).

It is important to note that it has been clearly established that a statement of utility in a specification must be accepted absent reasons why one skilled in the art would have reason to doubt the objective truth of such statement. *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA, 1974; “*Langer*”); *In re Marzocchi*, 439 F.2d 220, 224, 169 USPQ 367, 370 (CCPA, 1971). As clearly set forth in *Langer*:

As a matter of Patent Office practice, a specification which contains a disclosure of utility which corresponds in scope to the subject matter sought to be patented must be taken as sufficient to satisfy the utility requirement of § 101 for the entire claimed subject matter unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope.

Langer at 297, emphasis in original. As set forth in the MPEP, “Office personnel must provide evidence sufficient to show that the statement of asserted utility would be considered ‘false’ by a person of ordinary skill in the art” (MPEP, Eighth Edition at 2100-40, emphasis added). Absent such evidence from the Examiner, as the skilled artisan would readily understand that the present polymorphic markers have utility in forensic analysis, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Additionally, as set forth in the previous response, an additional example of the utility of the present nucleotide sequences, detailed in the specification on page 5, lines 24-26, is that the present nucleotide sequences have utility in assessing gene expression patterns using high-throughput DNA chips. The Examiner questions this asserted utility, stating that "one must know the biological significance of the polynucleotides which are being evaluated", and that "(w)ithout this information, the results of the transcript image are useless because one would not know if the polynucleotide expression should be increased or decreased" (Action bridging pages 4 and 5). This argument is flawed in at least two respects. First, expression profiling does not require a knowledge of the function of the particular nucleic acid on the chip - rather the gene chip indicates which DNA fragments are expressed at greater or lesser levels in two or more particular tissue types. Second, the particular cell types and controls in which the expression levels are assessed directly indicate to the skilled artisan whether "the polynucleotide expression should be increased or decreased". This is exactly how gene chips are used, and does not require undue experimentation on the part of the skilled artisan. The Examiner continues that "without knowing the significance of the instant polynucleotide or the activity of the encoded protein, using the claimed polynucleotide in a gene chip would not yield any useful information" (Action at page 5). However, this argument is thwarted by the fact that skilled artisans already have used and continue to use sequences such as Applicants in gene chip applications every day, without any information about the "polynucleotide or the activity of the encoded protein". It defies logic that skilled artisans would waste time and money by including such sequences on gene chips if they "would not yield any useful information". Therefore, these arguments completely fail to support the alleged lack of utility of the presently claimed compositions.

Applicants also pointed out in the previous response that although only one credible assertion of utility is needed to meet the requirements of 35 U.S.C. § 101 (*Raytheon v. Roper*, 220 USPQ 592 (Fed. Cir. 1983); *In re Gottlieb*, 140 USPQ 665 (CCPA 1964); *In re Malachowski*, 189 USPQ 432 (CCPA 1976); *Hoffman v. Klaus*, 9 USPQ2d 1657 (Bd. Pat. App. & Inter. 1988)), as a further example of the utility of the presently claimed polynucleotide, as described in the specification at least at page 2, lines 29-32, the present nucleotide sequences have a specific utility in "identification of coding sequence" and "mapping a unique gene to a particular chromosome". The Examiner also questions these utilities, stating that "using the claimed nucleic acids to produce the encoded proteins does not afford the claimed nucleic acids specific, substantial and well established utility, because, (*sic*)

Applicants do not disclose an activity for the encoded polypeptides, nor do they disclose the biological significance of said polypeptides” (Action at page 5). This argument once again **completely** mischaracterizes Applicants’ position. Applicants are **not** arguing that the present sequences have utility because they can be used “to produce the encoded proteins”, but **rather**, the presently claimed polynucleotide sequences have utility because they provide biologically validated empirical data (*e.g.*, showing which sequences are transcribed, spliced, and polyadenylated) that *specifically* define that portion of the corresponding genomic locus that actually encodes exon sequence. Equally significant is that the claimed polynucleotide sequences define how the encoded exons are actually spliced together to produce an active transcript (*i.e.*, the described sequences are useful for **functionally defining exon splice-junctions**). This is evidenced by the fact that SEQ ID NO: 1 can be used to map the 5 coding exons on chromosome 17 (present within two independent chromosome 17 clones; GenBank Accession Numbers AC087644 and AC090685; alignments and the first page from the GenBank reports are presented in **Exhibit A**). The specification details that “sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (*e.g.*, splice acceptor and/or donor sites), *etc.*, that can be used in diagnostics and pharmacogenomics” (specification at page 11, lines 1-6). Applicants respectfully submit that the practical scientific value of **biologically validated**, expressed, spliced, and polyadenylated mRNA sequences is readily apparent to those skilled in the relevant biological and biochemical arts. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Additionally, the present polynucleotides provide exquisite specificity in localizing the specific region of human chromosome 17 that contains the gene encoding the given polynucleotides, a utility not shared by virtually **any other** nucleic acid sequences. In fact, it is this specificity that makes this particular sequence so useful. Early gene mapping techniques relied on methods such as Giemsa staining to identify regions of chromosomes. However, such techniques produced genetic maps with a resolution of only 5 to 10 megabases, far too low to be of much help in identifying specific genes involved in disease. The skilled artisan readily appreciates the significant benefit afforded by markers that map a specific locus of the human genome, such as the present nucleic acid sequence. For further evidence in support of the Applicants’ position, the Examiner is requested to review, for example, section 3 of Venter *et al.* (2001, *Science* 291:1304, at pp. 1317-1321, including Fig. 11 at

pp.1324-1325), which demonstrates the significance of expressed sequence information in the structural analysis of genomic data. The presently claimed polynucleotide sequence defines a biologically validated sequence that provides a unique and specific resource for mapping the genome essentially as described in the Venter *et al.* article. Thus, the present claims clearly meet the requirements of 35 U.S.C. § 101.

Finally, as pointed out in the previous response, the requirements set forth in the Action for compliance with 35 U.S.C. § 101 do not comply with the requirements set forth by the Patent and Trademark Office (“the PTO”) itself for compliance with 35 U.S.C. § 101. While Applicants are well aware of the new Utility Guidelines set forth by the USPTO, Applicants respectfully point out that the current rules and regulations regarding the examination of patent applications is and always has been the patent laws as set forth in 35 U.S.C. and the patent rules as set forth in 37 C.F.R., not the Manual of Patent Examination Procedure or particular guidelines for patent examination set forth by the USPTO. Furthermore, it is the job of the judiciary, not the USPTO, to interpret these laws and rules. Applicants are unaware of any significant recent changes in either 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit that is in keeping with the new Utility Guidelines set forth by the USPTO. This is underscored by numerous patents that have been issued over the years that claim nucleic acid fragments that do not comply with the new Utility Guidelines. As examples of such issued U.S. Patents, the Examiner is invited to review U.S. Patent Nos. 5,817,479, 5,654,173, and 5,552,281 (each of which claims short polynucleotides), and recently issued U.S. Patent No. 6,340,583 (which includes no working examples), none of which contain examples of the “real-world” utilities that the Examiner seems to be requiring. As issued U.S. Patents are presumed to meet all of the requirements for patentability, including 35 U.S.C. §§ 101 and 112, first paragraph (see Section IV, below), Applicants submit that the present polynucleotides must also meet the requirements of 35 U.S.C. § 101. While Applicants understand that “each Patent Application is examined on its’ own merits” (Action at page 6), Applicants are unaware of any changes to 35 U.S.C. § 101, or in the interpretation of 35 U.S.C. § 101 by the Supreme Court or the Federal Circuit, since the issuance of these patents that render the subject matter claimed in these patents, which is similar to the subject matter in question in the present application, as suddenly non-statutory or failing to meet the requirements of 35 U.S.C. § 101. Thus, holding Applicants to a different standard of utility would be arbitrary and capricious, and, like other clear violations of due process, cannot stand.

For each of the foregoing reasons, Applicants submit that as the presently claimed nucleic acid molecules have been shown to have a substantial, specific, credible and well-established utility, the rejection of claims 1-4 and 6-13 under 35 U.S.C. § 101 has been overcome, and request that the rejection be withdrawn.

IV. Rejection of Claims 1-4 and 6-13 Under 35 U.S.C. § 112, First Paragraph

The Action next rejects claims 1-4 and 6-13 under 35 U.S.C. § 112, first paragraph, since allegedly one skilled in the art would not know how to use the invention, as the invention allegedly is not supported by a specific, substantial, and credible utility or a well-established utility. Applicants respectfully traverse.

Applicants submit that as claims 1-4 and 6-13 have been shown to have "a specific, substantial, and credible utility", as detailed in section III above, the present rejection of claims 1-4 and 6-13 under 35 U.S.C. § 112, first paragraph, cannot stand.

Applicants therefore request that the rejection of claims 1-4 and 6-13 under 35 U.S.C. § 112, first paragraph, be withdrawn.

V. Rejection of Claim 2 Under 35 U.S.C. § 112, Second Paragraph

The Action next rejects claim 2 under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the invention.

The Action rejects claim 2 as allegedly indefinite based on the term "highly stringent hybridization conditions", because the specific hybridization and washing conditions are not recited in the claim. Applicants once again stress that "a claim need not 'describe' the invention, such description being the role of the disclosure". *Orthokinetics, Inc. v. Safety Travel Chairs, Inc.*, 1 USPQ2d 1081, 1088 (Fed. Cir. 1986). However, while Applicants submit that the term is sufficiently definite, as a number of highly stringent hybridization conditions are defined in the specification and would be known to those of skill in the art, solely in order to progress the case more rapidly toward allowance the claim has been revised to specifically recite specific highly stringent hybridization conditions. As the specification provides specific teaching regarding such highly stringent hybridization conditions, at least at page 4, lines 15-22, Applicants submit that revised claim 2 even more clearly meets the requirements of 35 U.S.C. § 112, second paragraph. Applicants therefore request withdrawal of this rejection.


VI. Conclusion

The present document is a full and complete response to the Action. In conclusion, Applicants submit that, in light of the foregoing remarks, the present case is in condition for allowance, and such favorable action is respectfully requested. Should Examiner Hamud have any questions or comments, or believe that certain amendments of the claims might serve to improve their clarity, a telephone call to the undersigned Applicants' representative is earnestly solicited.

Respectfully submitted,

August 19, 2003

Date



David W. Hibler
Agent for Applicants

Reg. No. 41,071

LEXICON GENETICS INCORPORATED
(281) 863-3399

Customer # 24231

EXHIBIT "A"

Query= SEQ ID NO:1
(789 letters)

Sequences producing significant alignments:	Score (bits)	E Value
AC087644.4.65670.168042	<u>554</u>	e-155
AC090685.8.1.171140	<u>554</u>	e-155

>AC087644.4.65670.168042
Length = 102373

Score = 554 bits (279), Expect = e-155
Identities = 279/279 (100%)
Strand = Plus / Minus

Query: 362 ttctctctctcctaagtggaaacgacttccaaacagttgaggaaggcagtaatgtgaagt 421
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 85308 ttctctctctcctaagtggaaacgacttccaaacagttgaggaaggcagtaatgtgaagt 85249

Query: 422 tggtttgcaatgtgaaagccaacccccagggtcaaatagatgtggtacaaaaacagtagtc 481
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 85248 tggtttgcaatgtgaaagccaacccccagggtcaaatagatgtggtacaaaaacagtagtc 85189

Query: 482 tcctcgatttagagaaaagccgtcaccaaatacaacagacaagtgagtccttttcagctgt 541
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 85188 tcctcgatttagagaaaagccgtcaccaaatacaacagacaagtgagtccttttcagctgt 85129

Query: 542 caatcaccaaagtcgagaagcctgacaacggaacctacagttgtattgcaaagtcatttc 601
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 85128 caatcaccaaagtcgagaagcctgacaacggaacctacagttgtattgcaaagtcatttc 85069

Query: 602 tgaaaacggagagcttggactttcacctgattgttaaag 640
 |||||||||||||||||||||||||||||||||||||
Sbjct: 85068 tgaaaacggagagcttggactttcacctgattgttaaag 85030

Score = 547 bits (275), Expect = e-153
Identities = 277/279 (99%)
Strand = Plus / Minus

Query: 83 gttctgttttaactgtgaatggtaaaactgagaactatatcctggatactacacctggct 142
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 89743 gttctgttttaactgtgaatggtaaaactgagaactatatcctggatactacacctggct 89684

Query: 143 cccaagcatctctgatatgtgctgttcaaaaccacaccagagaggaagaactgctctgg 202
 |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct: 89683 cccaagcatctctgatatgtgctgttcaaaaccacaccagagaggaagaactgctctgg 89624

Query: 203 accgagaggaggggagagtggatttgaaatctgsaaacaamatcaattccagctctgtct 262
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 89623 accgagaggaggggagagtggatttgaaatctggaaacaaaatcaattccagctctgtct 89564

Query: 263 gtgtctcttccatcagtgaaaatgacaacggaatcagctttacctgcaggctggggaggg 322
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 89563 gtgtctcttccatcagtgaaaatgacaacggaatcagctttacctgcaggctggggaggg 89504

Query: 323 atcagtccgtgtccgttttcggtggtgctgaatgttactt 361
 ||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 89503 atcagtccgtgtccgttttcggtggtgctgaatgttactt 89465

Score = 211 bits (106), Expect = 7e-52
 Identities = 106/106 (100%)
 Strand = Plus / Minus

Query: 639 agataaaactgtgggtgtaccaatagagccattattgctgcatgtgttgatctttct 698
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 79129 agataaaactgtgggtgtaccaatagagccattattgctgcatgtgttgatctttct 79070

Query: 699 gacattgtgcttttgactgattgctagaagaaagaaaataatgaag 744
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 79069 gacattgtgcttttgactgattgctagaagaaagaaaataatgaag 79024

Score = 163 bits (82), Expect = 2e-37
 Identities = 83/84 (98%)
 Strand = Plus / Minus

Query: 1 atggcatggaagagcagtgtcataatgcaratgggaagatttcttctcttagtaatttta 60
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 92347 atggcatggaagagcagtgtcataatgcaaatgggaagatttcttctcttagtaatttta 92288

Query: 61 tttctgccacgtgagatgacaagt 84
 ||||||||||||||||||
 Sbjct: 92287 tttctgccacgtgagatgacaagt 92264

Score = 85.9 bits (43), Expect = 3e-14
 Identities = 43/43 (100%)
 Strand = Plus / Minus

Query: 743 agctctgcatgaaggataaagaccctcacagtgaaacagctct 785
 ||||||||||||||||||||||||||||||||||||||||||
 Sbjct: 77449 agctctgcatgaaggataaagaccctcacagtgaaacagctct 77407

>AC090685.8.1.171140
Length = 171140

Score = 554 bits (279), Expect = e-155
Identities = 279/279 (100%)
Strand = Plus / Minus

Query: 362 ttctctctctcttaagtggaaacgacttccaaacagttgaggaaggcagtaatgtgaagt 421
 |||||
Sbjct: 56850 ttctctctctcttaagtggaaacgacttccaaacagttgaggaaggcagtaatgtgaagt 56791

Query: 422 tggtttgcaatgtgaaagccaacccccagggtcaaatagatgtggtacaaaaacagtagtc 481
 |||||
Sbjct: 56790 tggtttgcaatgtgaaagccaacccccagggtcaaatagatgtggtacaaaaacagtagtc 56731

Query: 482 tcctcgatttagagaaaagccgtcaccaaataccaacagacaagtgagtccttttcagctgt 541
 |||||
Sbjct: 56730 tcctcgatttagagaaaagccgtcaccaaataccaacagacaagtgagtccttttcagctgt 56671

Query: 542 caatcaccaaagtcgagaagcctgacaacggaacctacagttgtattgcaaagtcatttc 601
 |||||
Sbjct: 56670 caatcaccaaagtcgagaagcctgacaacggaacctacagttgtattgcaaagtcatttc 56611

Query: 602 tgaaaacggagagcttggactttcacctgattgttaaag 640
 |||||
Sbjct: 56610 tgaaaacggagagcttggactttcacctgattgttaaag 56572

Score = 547 bits (275), Expect = e-153
Identities = 277/279 (99%)
Strand = Plus / Minus

Query: 83 gttctgttttaactgtgaatggtaaaactgagaactatatcctggatactacacctggct 142
 |||||
Sbjct: 61293 gttctgttttaactgtgaatggtaaaactgagaactatatcctggatactacacctggct 61234

Query: 143 cccaagcatctctgatatgtgctgttcaaaaccacaccagagaggaagaactgctctggt 202
 |||||
Sbjct: 61233 cccaagcatctctgatatgtgctgttcaaaaccacaccagagaggaagaactgctctggt 61174

Query: 203 accgagaggaggggagagtggatttgaaatctgsaaacaamatcaattccagctctgtct 262
 |||||
Sbjct: 61173 accgagaggaggggagagtggatttgaaatctgsaaacaaatcaattccagctctgtct 61114

Query: 263 gtgtctcttccatcagtgaaaatgacaacggaatcagctttacctgcaggctggggaggg 322
|||||
Sbjct: 61113 gtgtctcttccatcagtgaaaatgacaacggaatcagctttacctgcaggctggggaggg 61054

Query: 323 atcagtcctgtgtccgttttcggtggtgctgaatgttactt 361
|||||
Sbjct: 61053 atcagtcctgtgtccgttttcggtggtgctgaatgttactt 61015

Score = 211 bits (106), Expect = 7e-52
Identities = 106/106 (100%)
Strand = Plus / Minus

Query: 639 agataaaactgtgggtgtaccaatagagccattattgctgcatgtgttgatctttct 698
|||||
Sbjct: 50671 agataaaactgtgggtgtaccaatagagccattattgctgcatgtgttgatctttct 50612

Query: 699 gacattgtgctttggactgattgctagaagaaagaaaataatgaag 744
|||||
Sbjct: 50611 gacattgtgctttggactgattgctagaagaaagaaaataatgaag 50566

Score = 163 bits (82), Expect = 2e-37
Identities = 83/84 (98%)
Strand = Plus / Minus

Query: 1 atggcatggaagagcagtggtcataatgcaratgggaagatttcttctcttagtaatttta 60
|||||
Sbjct: 63900 atggcatggaagagcagtggtcataatgcaaatgggaagatttcttctcttagtaatttta 63841

Query: 61 tttctgccacgtgagatgacaagt 84
|||||
Sbjct: 63840 tttctgccacgtgagatgacaagt 63817

Score = 85.9 bits (43), Expect = 3e-14
Identities = 43/43 (100%)
Strand = Plus / Minus

Query: 743 agctctgcatgaaggataaagaccctcacagtgaacagctct 785
|||||
Sbjct: 48991 agctctgcatgaaggataaagaccctcacagtgaacagctct 48949



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bio

Search for

Limits Preview/Index History Clipboard Details

Display Show: Send to

1: AC087644. Homo sapiens chro...[gi:22655825]

Links

LOCUS AC087644 102286 bp DNA linear PRI 03-SEP-2002

DEFINITION Homo sapiens chromosome 17, clone RP11-403E9, complete sequence.

ACCESSION AC087644

VERSION AC087644.8 GI:22655825

KEYWORDS HTG.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 102286)

AUTHORS Birren,B., Nusbaum,C. and Lander,E.

TITLE Homo sapiens chromosome 17, clone RP11-403E9

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 102286)

AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,S., Barna,N., Bastien,V., Boguslavkiy,L., Boukhgalter,B., Brown,A., Camarata,J., Campopiano,A., Choepel,Y., Colangelo,M., Collins,S., Collymore,A., Cooke,P., DeArellano,K., Dewar,K., Diaz,J.S., Dodge,S., Faro,S., Ferreira,P., FitzHugh,W., Gage,D., Galagan,J., Gardyna,S., Ginde,S., Goyette,M., Graham,L., Grand-Pierre,N., Hagos,B., Heaford,A., Horton,L., Hulme,W., Iliev,I., Johnson,R., Jones,C., Karatas,A., LaRocque,K., Lamazares,R., Landers,T., Lehoczy,J., Levine,R., Liu,G., MacLean,C., Macdonald,P., Marquis,N., Matthews,C., McCarthy,M., McEwan,P., McKernan,K., McPheeters,R., Meldrim,J., Meneus,L., Mihova,T., Mlenga,V., Murphy,T., Naylor,J., Nguyen,C., Norbu,C., Norman,C.H., O'Connor,T., O'Donnell,P., O'Neil,D., Oliver,J., Peterson,K., Phunkhang,P., Pierre,N., Pollara,V., Raymond,C., Retta,R., Rieback,M., Riley,R., Rise,C., Rogov,P., Roman,J., Rosetti,M., Roy,A., Santos,R., Schauer,S., Schupback,R., Seaman,S., Severy,P., Sougnez,C., Spencer,B., Stange-Thomann,N., Stojanovic,N., Strauss,N., Subramanian,A., Talamas,J., Tesfaye,S., Theodore,J., Travers,M., Travis,N., Trigilio,J., Vassiliev,H., Viel,R., Vo,A., Wilson,B., Wu,X., Wyman,D., Ye,W.J., Young,G., Zainoun,J., Zembek,L., Zimmer,A. and Zody,M.

TITLE Direct Submission

JOURNAL Submitted (15-JAN-2001) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA

REFERENCE 3 (bases 1 to 102286)

AUTHORS Birren,B., Nusbaum,C., Lander,E., Ali,A., Allen,N., Anderson,S., Barna,N., Bastien,V., Bloom,T., Boguslavkiy,L., Boukhgalter,B., Camarata,J., Chang,J., Chazaro,B., Choepel,Y., Collymore,A., Cook,A., Cooke,P., DeArellano,K., Dewar,K., Diaz,J.S., Dodge,S., Faro,S., Ferreira,P., FitzGerald,M., Gage,D., Galagan,J., Gardyna,S., Gord,S., Graham,L., Grand-Pierre,N., Hagos,B., Horton,L., Hulme,W., Iliev,I., Johnson,R., Jones,C., Kamat,A., Karatas,A., Kells,C., Landers,T., Levine,R., Lindblad-Toh,K.,



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bio

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Fe

☐ 1: AC090685. Homo sapiens chro...[gi:18698797]

Links

LOCUS AC090685 171140 bp DNA linear PRI 17-FEB-2002
 DEFINITION Homo sapiens chromosome 17, clone RP11-252024, complete sequence.
 ACCESSION AC090685
 VERSION AC090685.8 GI:18698797
 KEYWORDS HTG.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 171140)
 AUTHORS Birren,B., Linton,L., Nusbaum,C. and Lander,E.
 TITLE Homo sapiens chromosome 17, clone RP11-252024
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 171140)
 AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,S.,
 Barna,N., Bastien,V., Boguslavkiy,L., Boukhgalter,B., Brown,A.,
 Camarata,J., Campopiano,A., Choepel,Y., Colangelo,M., Collins,S.,
 Collymore,A., Cooke,P., DeArellano,K., Dewar,K., Diaz,J.S.,
 Dodge,S., Faro,S., Ferreira,P., FitzHugh,W., Gage,D., Galagan,J.,
 Gardyna,S., Ginde,S., Goyette,M., Graham,L., Grand-Pierre,N.,
 Hagos,B., Heaford,A., Horton,L., Hulme,W., Iliev,I., Johnson,R.,
 Jones,C., Karatas,A., LaRocque,K., Lamazares,R., Landers,T.,
 Lehoczky,J., Levine,R., Liu,G., MacLean,C., Macdonald,P.,
 Marquis,N., Matthews,C., McCarthy,M., McEwan,P., McKernan,K.,
 McPheeters,R., Meldrim,J., Meneus,L., Mihova,T., Mlenga,V.,
 Murphy,T., Naylor,J., Nguyen,C., Norbu,C., Norman,C.H.,
 O'Connor,T., O'Donnell,P., O'Neil,D., Oliver,J., Peterson,K.,
 Phunkhang,P., Pierre,N., Pollara,V., Raymond,C., Retta,R.,
 Rieback,M., Riley,R., Rise,C., Rogov,P., Roman,J., Rosetti,M.,
 Roy,A., Santos,R., Schauer,S., Schupback,R., Seaman,S., Severy,P.,
 Sougnez,C., Spencer,B., Stange-Thomann,N., Stojanovic,N.,
 Strauss,N., Subramanian,A., Talamas,J., Tesfaye,S., Theodore,J.,
 Travers,M., Travis,N., Trigilio,J., Vassiliev,H., Viel,R., Vo,A.,
 Wilson,B., Wu,X., Wyman,D., Ye,W.J., Young,G., Zainoun,J.,
 Zembek,L., Zimmer,A. and Zody,M.
 TITLE Direct Submission
 JOURNAL Submitted (08-MAR-2001) Whitehead Institute/MIT Center for Genome
 Research, 320 Charles Street, Cambridge, MA 02141, USA
 REFERENCE 3 (bases 1 to 171140)
 AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Ali,A., Allen,N.,
 Anderson,S., Barna,N., Bastien,V., Boguslavkiy,L., Boukhgalter,B.,
 Brown,A., Camarata,J., Campopiano,A., Chang,J., Chazaro,B.,
 Choepel,Y., Colangelo,M., Collins,S., Collymore,A., Cook,A.,
 Cooke,P., DeArellano,K., Dewar,K., Diaz,J.S., Dodge,S., Faro,S.,
 Ferreira,P., FitzHugh,W., Gage,D., Galagan,J., Gardyna,S.,
 Ginde,S., Gord,S., Goyette,M., Graham,L., Grand-Pierre,N.,
 Hagos,B., Heaford,A., Horton,L., Hulme,W., Iliev,I., Johnson,R.,